Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine

项目概要 疫苗拯救了数百万人的生命。然而，有许多疾病是疫苗无法预防的。 目前，全球范围内的 COVID-19 大流行痛苦地提醒我们需要 针对新出现疾病的疫苗。随着人们对疫苗安全性的日益重视，下一代疫苗 设计越来越关注亚单位抗原。因为亚基表位往往具有较低的 免疫原性，免疫原性载体对于将所需抗原递送至免疫系统并使其发挥作用至关重要。 增强免疫反应。然而，经过验证的可用运营商非常少。 临床研究。在这个 SBIR 第一阶段项目中，Iaso Therapeutics, Inc. 将专注于开发专有的 噬菌体突变体 Qβ (mQβ) 病毒样颗粒作为结合疫苗的平台技术。在目标 1 中， 将为 mQβ 的表达、纯化和长期储存建立稳健的方案。另外，头 将进行与头部的比较，以证明 mQβ 可以引发更高水平的抗体 到当前的基准运营商。在目标 2 中，将应用强大的 mQβ 平台来递送沙门氏菌 相关聚糖作为针对多种常见致病性沙门氏菌菌株的潜在疫苗。的 将优化疫苗以增强对沙门氏菌感染的保护。当开发成功后，这 项目将建立 mQβ 作为疫苗开发有吸引力的免疫原性载体，并提供重要的 抗沙门氏菌疫苗的临床前数据。

Project summary Vaccines have saved millions of lives. However, there are many diseases against which vaccines are not yet available, with the current COVID-19 pandemic in the world serving as a painful reminder of the need for vaccines against emerging diseases. With the growing emphasis on vaccine safety, next-generation vaccine designs have been increasingly focusing on subunit antigens. Because subunit epitopes tend to have lower immunogenicity, immunogenic carriers are critical to deliver the desired antigen to the immune system and to enhance the immune responses. However, there are very few carriers available that have been validated in clinical studies. In this SBIR phase I project, Iaso Therapeutics, Inc. will focus on the development of a proprietary bacteriophage mutant Qβ (mQβ) virus like particle as a platform technology for conjugate vaccines. In aim 1, robust protocols will be established for expression, purification, and long-term storage of mQβ. In addition, head to head comparison will be performed to demonstrate that mQβ can elicit higher levels of antibodies as compared to current benchmark carriers. In aim 2, the powerful mQβ platform will be applied to deliver Salmonella associated glycans as potential vaccines against multiple strains of common pathogenic Salmonella. The vaccine will be optimized to enhance protection from Salmonella infection. When successfully developed, this project will establish mQβ as an attractive immunogenic carrier for vaccine development and provide important pre-clinical data for anti-Salmonella vaccines.